Clinical Trials Browser

Phase 1/2 × Recurrence × camrelizumab × Clear all

NCT04476459 2021-03-15

Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

Phase 1/2 Unknown

Recurrence, Lymphoma, Large B-Cell, Diffuse, Pyloric Stenosis, Hypertrophic